{"id":56885,"date":"2026-02-11T21:26:54","date_gmt":"2026-02-11T13:26:54","guid":{"rendered":"https:\/\/flcube.com\/?p=56885"},"modified":"2026-02-11T21:26:56","modified_gmt":"2026-02-11T13:26:56","slug":"gilead-reports-2025-revenue-growth-to-29-4-billion-on-hiv-strength-veklury-plunges-49","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56885","title":{"rendered":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%"},"content":{"rendered":"\n<p><strong>Gilead Sciences, Inc.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ:\u202fGILD<\/a><\/strong>) announced <strong>fourth quarter and full-year 2025 financial results<\/strong>, with <strong>total revenues rising 2% to USD\u202f29.4 billion<\/strong> driven by <strong>HIV and Liver Disease portfolio strength<\/strong>, offset by a <strong>sharp 49% decline in Veklury (remdesivir)<\/strong> sales as COVID-19 hospitalizations normalized. The biotechnology leader issued <strong>2026 guidance<\/strong> of <strong>USD\u202f29.6\u201330.0 billion<\/strong> in product sales, signaling <strong>stable growth trajectory<\/strong> excluding pandemic-related volatility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YoY Change<\/th><th>Key Driver<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>USD\u202f29.4 billion<\/td><td><strong>+2%<\/strong><\/td><td>HIV and Liver Disease growth offsetting Veklury decline<\/td><\/tr><tr><td><strong>Q4 Revenues<\/strong><\/td><td>USD\u202f7.9 billion<\/td><td><strong>+5%<\/strong><\/td><td>Quarterly momentum in core franchises<\/td><\/tr><tr><td><strong>HIV Product Sales<\/strong><\/td><td>USD\u202f20.8 billion<\/td><td><strong>+6%<\/strong><\/td><td>Biktarvy and Descovy market share gains<\/td><\/tr><tr><td><strong>Liver Disease<\/strong><\/td><td>USD\u202f3.2 billion<\/td><td><strong>+6%<\/strong><\/td><td>Hepatitis B and C portfolio stability<\/td><\/tr><tr><td><strong>Cell Therapy<\/strong><\/td><td>USD\u202f1.8 billion<\/td><td><strong>-7%<\/strong><\/td><td>Yescarta growth offset by broader portfolio pressures<\/td><\/tr><tr><td><strong>Trodelvy (ADC)<\/strong><\/td><td>USD\u202f1.4 billion<\/td><td><strong>+6%<\/strong><\/td><td>Solid tumor expansion<\/td><\/tr><tr><td><strong>Veklury<\/strong><\/td><td>USD\u202f911 million<\/td><td><strong>-49%<\/strong><\/td><td>Post-pandemic demand normalization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-franchise-deep-dive\">Franchise Deep Dive<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hiv-core-growth-engine\">HIV: Core Growth Engine<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>2025 Sales<\/th><th>YoY Change<\/th><th>Strategic Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Biktarvy<\/strong><\/td><td>USD\u202f14.3 billion<\/td><td><strong>+7%<\/strong><\/td><td><strong>#1 prescribed HIV regimen globally<\/strong>; single-tablet regimen dominance<\/td><\/tr><tr><td><strong>Descovy<\/strong><\/td><td>USD\u202f2.8 billion<\/td><td><strong>+31%<\/strong><\/td><td>PrEP and HIV treatment backbone; tenofovir alafenamide safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV Market Leadership:<\/strong> Gilead maintains <strong>>50% global HIV market share<\/strong>; Biktarvy&#8217;s <strong>high barrier to resistance<\/strong> and <strong>tolerability<\/strong> drive prescriber loyalty and payer preference<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cell-therapy-mixed-signals\">Cell Therapy: Mixed Signals<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>2025 Sales<\/th><th>YoY Change<\/th><th>Clinical Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Yescarta<\/strong><\/td><td>USD\u202f1.5 billion<\/td><td><strong>+5%<\/strong><\/td><td>CD19 CAR-T in LBCL; label expansion to PCNSL (Feb\u202f2026)<\/td><\/tr><tr><td><strong>Tecartus<\/strong><\/td><td>USD\u202f344 million<\/td><td><strong>+15%<\/strong><\/td><td>BCMA CAR-T in mantle cell lymphoma; growth trajectory<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Pressure:<\/strong> Overall Cell Therapy decline reflects <strong>competition from bispecific antibodies<\/strong> (epcoritamab, glofitamab) and <strong>manufacturing capacity constraints<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-trodelvy-adc-validation\">Trodelvy: ADC Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sacituzumab govitecan<\/strong> maintains <strong>6% growth<\/strong> in <strong>triple-negative breast cancer and urothelial carcinoma<\/strong>; faces <strong>datopotamab deruxtecan competition<\/strong> in HR+\/HER2- breast cancer<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2026-guidance-amp-strategic-outlook\">2026 Guidance &amp; Strategic Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026 Guidance<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Product Sales<\/strong><\/td><td>USD\u202f29.6\u201330.0 billion<\/td><td><strong>Stable core business<\/strong>; low-single-digit growth<\/td><\/tr><tr><td><strong>Ex-Veklury Product Sales<\/strong><\/td><td>USD\u202f29.0\u201329.4 billion<\/td><td><strong>Normalized COVID-19 impact<\/strong>; sustainable HIV\/oncology trajectory<\/td><\/tr><tr><td><strong>Key Catalysts<\/strong><\/td><td>Yescarta label expansions; Trodelvy TNBC data; HIV long-acting injectable launch<\/td><td>Innovation pipeline execution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Gilead Sciences&#8217; 2026 revenue performance, HIV franchise sustainability, and cell therapy competitive positioning. Actual results may differ due to generic competition in HIV, pricing pressure from national reimbursement programs, and biosimilar entry in oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,226,1025],"class_list":["post-56885","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56885\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56885\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T13:26:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T13:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%\",\"datePublished\":\"2026-02-11T13:26:54+00:00\",\"dateModified\":\"2026-02-11T13:26:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1103.webp\",\"keywords\":[\"Finanical Reports\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56885#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56885\",\"name\":\"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1103.webp\",\"datePublished\":\"2026-02-11T13:26:54+00:00\",\"dateModified\":\"2026-02-11T13:26:56+00:00\",\"description\":\"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56885\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56885#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49% - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56885","og_locale":"en_US","og_type":"article","og_title":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%","og_description":"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.","og_url":"https:\/\/flcube.com\/?p=56885","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T13:26:54+00:00","article_modified_time":"2026-02-11T13:26:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56885#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56885"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%","datePublished":"2026-02-11T13:26:54+00:00","dateModified":"2026-02-11T13:26:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56885"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56885#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","keywords":["Finanical Reports","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56885#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56885","url":"https:\/\/flcube.com\/?p=56885","name":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56885#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56885#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","datePublished":"2026-02-11T13:26:54+00:00","dateModified":"2026-02-11T13:26:56+00:00","description":"Gilead Sciences, Inc. (NASDAQ:\u202fGILD) announced fourth quarter and full-year 2025 financial results, with total revenues rising 2% to USD\u202f29.4 billion driven by HIV and Liver Disease portfolio strength, offset by a sharp 49% decline in Veklury (remdesivir) sales as COVID-19 hospitalizations normalized. The biotechnology leader issued 2026 guidance of USD\u202f29.6\u201330.0 billion in product sales, signaling stable growth trajectory excluding pandemic-related volatility.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56885#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56885"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56885#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","width":1080,"height":608,"caption":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56885#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56885"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56885\/revisions"}],"predecessor-version":[{"id":56887,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56885\/revisions\/56887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56886"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}